跳至主要内容
临床试验/NCT05661019
NCT05661019已完成不适用

Clinical Feasibility of the Myotrace Measurement

Philips Clinical & Medical Affairs Global1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2024年5月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
56
试验地点
1
主要终点
Evaluate Feasibility of the MYOTRACE NRD index

研究概览

简要总结

To evaluate the feasibility of the MYOTRACE NRD (Neural Respiratory Drive) index as an aid to assess the respiratory status of a patient (improving or stable versus deteriorating) as compared to a specialist in thoracic medicine's evaluation in a general care setting.

详细描述

This clinical investigation is designed as a single-arm evaluation of a diseased patient population. This study includes a longitudinal observation study of patients who enter the general ward (admission) until they leave the hospital (discharge).

This study includes standard patient care by the hospital staff with addition of Myotrace measurement, accelerometry and respiratory rate measurement via respiration belt during the NRD measurement.

The primary endpoint of the study is the Neural Respiratory Drive (NRD) index. This index will offline be compared to the specialist in thoracic medicine's assessment of the patient's health status after study closure. The General Ward care team will be blinded to the index values during the study. Re-admission information (i.e. 14 days after discharge) will be collected as well and used in the comparison with NRD index and specialist in thoracic medicine evaluation. Furthermore, the site will be asked to make note of patient events during study participation that are important for the study and study measurements.

The secondary endpoints of the study are the spot-check measurements, other objective and subjective measurements, and the subjective evaluation (e.g. experiences, preferences, acceptance, etc) of the Myotrace measurement protocol/procedures by the healthcare professionals and patients.

In total 50-60 patients will be enrolled.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18+, fluent knowledge of English or German.
  • Group A: Obstructive ventilatory disorders (conditions resulting in an increased load on the respiratory muscle pump due to hyperinflation ± pronounced hypoxaemia)
  • Acute exacerbation of COPD (pronounced hypoxia OR acute or acute on chronic hypercapnic respiratory failure)
  • Exacerbation of asthma bronchiale
  • Exacerbation of non-CF-bronchiectasis (infectious)
  • Infectious exacerbation of lung disease in cystic fibrosis
  • Group B: Conditions with an increase in NRD due to an impairment in gas exchange (particularly die to diffusion limitation and/or ventilation-perfusion-mismatch
  • Exacerbation of an interstitial lung disease (e.g. Idiopathic pulmonary fibrosis (IPF), Non Specific Interstitial Pneumonia (NSIP), Connective tissue disease- associated interstitial lung disease CTD-ILD)
  • Worsening of pulmonary arterial hypertension World Health Organisation (WHO) group 1 (e.g. due decompensated heart failure)
  • Acute pulmonary embolism
  • Pneumonia (resulting in hypoxaemia)

排除标准

  • Obesity hypoventilation syndrome (rationale: NRD decreased)
  • Obesity WHO III with Body Mass Index (BMI) > 40 kg/m2 (rationale: surface EMG signal quality low)
  • Hypercapnic respiratory failure due to hypoventilation of central origin, e.g. opiate-induced, Congenital central hypoventilation syndrome, post stroke (rationale: central respiratory control affected)
  • Neuromuscular disease affecting respiratory muscles, e.g. motor neurone disease, muscular dystrophy type Duchenne etc. (rationale: EMG signal quality etc. different)
  • Decompensated heart failure with atrial fibrillation (rationale: central breathing disturbance common)
  • Patients on chronic opioid therapy (e.g. chronic pain, methadone etc.) (rationale: reduced NRD)
  • Self reported pregnancy

结局指标

主要结局

Evaluate Feasibility of the MYOTRACE NRD index

时间窗: Mar 2024 (anticipated to be know at end of study)

to evaluate the feasibility of the MYOTRACE NRD index as an aid to assess the respiratory status of a patient as compared to a specialist in thoracic medicine's evaluation in a general care setting.

次要结局

  • Added value of NRD index(Mar 2024 (anticipated to be know at end of study))
  • Assess the viability of the MYOTRACE measurement protocol within the spot check practice(Mar 2024 (anticipated to be know at end of study))
  • Healthcare/patient satisfaction(Mar 2024 (anticipated))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Clinical Feasibility of the Myotrace Measurement | 临床试验